問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Rheumatology

China Medical University Hospital (在職)

Division of Rheumatology

Division of General Internal Medicine

更新時間：2023-09-19

陳得源Der-Yuan, Chen
  • Principal Investigator
  • Clinical Trial Experience (year)

  • 095959@tool.caaumed.org.tw

Recruiting Trial

16Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳得源

Taichung Veterans General Hospital

Division of Rheumatology

List

27Cases

2016-10-01 - 2020-03-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2006-03-01 - 2012-03-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2008-02-01 - 2010-09-01

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2007-05-01 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Study ended11Sites

2015-09-01 - 2018-07-31

Phase II

A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate to Severe Active Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    ALX-0061

Participate Sites
7Sites

Terminated5Sites

黃春明
China Medical University Hospital-Taipei

未分科

2011-02-01 - 2017-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-08-01 - 2016-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2008-08-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-07-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2011-10-01 - 2012-11-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB